November 13, 2019
REDWOOD CITY, Calif. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage ...
Read MoreOctober 25, 2019
REDWOOD CITY, Calif. , Oct. 25, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), ...
Read MoreOctober 23, 2019
REDWOOD CITY, Calif. , Oct. 23, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), (“Soleno” or the “Company”), ...
Read More
Developing novel therapeutics for the treatment of rare diseases.
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock